Detalhe da pesquisa
1.
Bruton tyrosine kinase inhibitors preserve anti-CD19 chimeric antigen receptor T-cell functionality and reprogram tumor micro-environment in B-cell lymphoma.
Cytotherapy
; 25(7): 739-749, 2023 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-37074239
2.
IL-10 plus the EASIX score predict bleeding events after anti-CD19 CAR T-cell therapy.
Ann Hematol
; 102(12): 3575-3585, 2023 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-37814134
3.
Adverse effects in hematologic malignancies treated with chimeric antigen receptor (CAR) T cell therapy: a systematic review and Meta-analysis.
BMC Cancer
; 22(1): 98, 2022 Jan 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-35073859
4.
Comparative efficacy and tolerability of front-line treatments for newly diagnosed chronic-phase chronic myeloid leukemia: an update network meta-analysis.
BMC Cancer
; 19(1): 849, 2019 Aug 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-31462241
5.
Anti-CD19 chimeric antigen receptor-modified T-cell therapy bridging to allogeneic hematopoietic stem cell transplantation for relapsed/refractory B-cell acute lymphoblastic leukemia: An open-label pragmatic clinical trial.
Am J Hematol
; 94(10): 1113-1122, 2019 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-31321805
6.
Multiple immunoglobulin isotype switch after bispecific CAR-T cell therapy in multiple myeloma-A case report.
Br J Haematol
; 200(4): 528-531, 2023 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36210354
7.
Global Regulation of Differential Gene Expression by c-Abl/Arg Oncogenic Kinases.
Med Sci Monit
; 23: 2625-2635, 2017 May 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-28555614
8.
Off-the-shelf CAR-T cell therapies for relapsed or refractory B-cell malignancies: latest update from ASH 2023 annual meeting.
J Hematol Oncol
; 17(1): 29, 2024 May 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-38711046
9.
Treatment of multiple myeloma: What is the impact on T-cell function?
Ther Adv Hematol
; 15: 20406207241245194, 2024.
Artigo
em Inglês
| MEDLINE | ID: mdl-38721038
10.
Bispecific CS1-BCMA CAR-T cells are clinically active in relapsed or refractory multiple myeloma.
Leukemia
; 38(1): 149-159, 2024 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37848634
11.
Targeting autophagy overcomes cancer-intrinsic resistance to CAR-T immunotherapy in B-cell malignancies.
Cancer Commun (Lond)
; 44(3): 408-432, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38407943
12.
Targeting CD22 for B-cell hematologic malignancies.
Exp Hematol Oncol
; 12(1): 90, 2023 Oct 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-37821931
13.
Allogenic and autologous anti-CD7 CAR-T cell therapies in relapsed or refractory T-cell malignancies.
Blood Cancer J
; 13(1): 61, 2023 04 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-37095094
14.
Novel CD19-specific γ/δ TCR-T cells in relapsed or refractory diffuse large B-cell lymphoma.
J Hematol Oncol
; 16(1): 5, 2023 01 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-36681817
15.
Therapeutic targets and signaling pathways of active components of QiLing decoction against castration-resistant prostate cancer based on network pharmacology.
PeerJ
; 10: e13481, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35782093
16.
Case Report: ITP Treatment After CAR-T Cell Therapy in Patients With Multiple Myeloma.
Front Immunol
; 13: 898341, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35784357
17.
Timing of Tocilizumab Administration Under the Guidance of IL-6 in CAR-T Therapy for R/R Acute Lymphoblastic Leukemia.
Front Immunol
; 13: 914959, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35799791
18.
PiggyBac-Generated CAR19-T Cells Plus Lenalidomide Cause Durable Complete Remission of Triple-Hit Refractory/Relapsed DLBCL: A Case Report.
Front Immunol
; 12: 599493, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-34113336
19.
A bispecific CAR-T cell therapy targeting BCMA and CD38 in relapsed or refractory multiple myeloma.
J Hematol Oncol
; 14(1): 161, 2021 10 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-34627333
20.
[Application Advance of Flow Cytometry in the CAR-T Cell Therapy--Review].
Zhongguo Shi Yan Xue Ye Xue Za Zhi
; 28(1): 329-332, 2020 Feb.
Artigo
em Zh
| MEDLINE | ID: mdl-32027298